Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Down-regulation of Fibulin-5 is associated with aortic dilation: role of inflammation and epigenetics

  • Orriols, Mar
  • Varona, Saray
  • Martí-Pàmies, Ingrid
  • Galán, María
  • Guadall, Anna
  • Escudero, José Román
  • Martín-Ventura, José Luis
  • Camacho, Mercedes
  • Vila, Luis
  • Martínez-González, José
  • Rodríguez-Sinovas, Cristina
Aims Destructive remodelling of extracellular matrix (ECM) and inflammation lead to dilation and ultimately abdominal aortic aneurysm (AAA). Fibulin-5 (FBLN5) mediates cell–ECM interactions and elastic fibre assembly and is critical for ECM remodelling. We aimed to characterize FBLN5 regulation in human AAA and analyse the underlying mechanisms. Methods and results FBLN5 expression was significantly decreased in human aneurysmatic aortas compared with healthy vessels. Local FBLN5 knockdown promoted aortic dilation and enhanced vascular expression of inflammatory markers in Ang II-infused C57BL/6J mice. Inflammatory stimuli down-regulated FBLN5 expression and transcriptional activity in human aortic vascular smooth muscle cells (VSMC). Further, aortic FBLN5 expression was reduced in LPS-challenged mice. A SOX response element was critical for FBLN5 promoter activity. The SOX9 expression pattern in human AAA parallels that of FBLN5, and like FBLN5, it was reduced in TNFα-stimulated VSMC. Interestingly, SOX9 over-expression prevented the cytokine-mediated reduction of FBLN5 expression and transcription. The inhibition of Class I histone deacetylases (HDACs) by MS-275 or gene silencing attenuated the inflammation-mediated decrease of FBLN5 expression in VSMC and in the vascular wall. Consistently, HDAC inhibition counteracted the reduction of SOX9 expression induced by inflammatory stimuli and prevented the TNFα-mediated decrease in the binding of SOX9 to FBLN5 promoter normalizing FBLN5 expression. Conclusion We evidence the deregulation of FBLN5 in human AAA and identify a SOX9/HDAC-dependent mechanism involved in the down-regulation of FBLN5 by inflammation. HDAC inhibitors or pharmacological approaches that aimed to preserve FBLN5 could be useful to prevent the disorganization of ECM induced by inflammation in AAA., This work was supported by the Spanish Ministerio de Economía y Competitividad (MINECO)-Instituto de Salud Carlos III (ISCIII) (grants PI15/01016, PI12/01952, SAF2012-40127, SAF2013-46707-R, SAF2015-64767-R, RD12/0042/0053, RD12/0042/0051 and RD12/0042/0038). A.G. and M.G. were supported by funds provided by ISCIII (PFIS and Sara Borrell programs, respectively). The study was co-founded by Fondo Europeo de Desarrollo Regional (FEDER), a way to make Europe., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Lysyl Oxidase Induces Vascular Oxidative Stress and Contributes to Arterial Stiffness and Abnormal Elastin Structure in Hypertension: Role of p38MAPK

  • Martínez-Revelles, Sonia
  • García-Redondo, Ana B.
  • Avendaño, María S.
  • Varona, Saray
  • Palao, Teresa
  • Orriols, Mar
  • Roque, Fernanda R.
  • Fortuño, Ana
  • Touyz, Rhian M.
  • Martínez-González, José
  • Salaices, Mercedes
  • Rodríguez-Sinovas, Cristina
  • Briones, Ana M.
Aims: Vascular stiffness, structural elastin abnormalities, and increased oxidative stress are hallmarks of hypertension. Lysyl oxidase (LOX) is an elastin crosslinking enzyme that produces H2O2 as a by-product. We addressed the interplay between LOX, oxidative stress, vessel stiffness, and elastin. Results: Angiotensin II (Ang II)-infused hypertensive mice and spontaneously hypertensive rats (SHR) showed increased vascular LOX expression and stiffness and an abnormal elastin structure. Mice over-expressing LOX in vascular smooth muscle cells (TgLOX) exhibited similar mechanical and elastin alterations to those of hypertensive models. LOX inhibition with β-aminopropionitrile (BAPN) attenuated mechanical and elastin alterations in TgLOX mice, Ang II-infused mice, and SHR. Arteries from TgLOX mice, Ang II-infused mice, and/or SHR exhibited increased vascular H2O2 and O2 .− levels, NADPH oxidase activity, and/or mitochondrial dysfunction. BAPN prevented the higher oxidative stress in hypertensive models. Treatment of TgLOX and Ang II-infused mice and SHR with the mitochondrial-targeted superoxide dismutase mimetic mito-TEMPO, the antioxidant apocynin, or the H2O2 scavenger polyethylene glycol-conjugated catalase (PEG-catalase) reduced oxidative stress, vascular stiffness, and elastin alterations. Vascular p38 mitogen-activated protein kinase (p38MAPK) activation was increased in Ang II-infused and TgLOX mice and this effect was prevented by BAPN, mito-TEMPO, or PEG-catalase. SB203580, the p38MAPK inhibitor, normalized vessel stiffness and elastin structure in TgLOX mice. Innovation: We identify LOX as a novel source of vascular reactive oxygen species and a new pathway involved in vascular stiffness and elastin remodeling in hypertension. Conclusion: LOX up-regulation is associated with enhanced oxidative stress that promotes p38MAPK activation, elastin structural alterations, and vascular stiffness. This pathway contributes to vascular abnormalities in hypertension. Antioxid. Redox Signal. 27, 379–397., This project was supported by the Spanish Ministerio de Economía y Competitividad (MINECO) (SAF2012-36400; SAF2015-64767-R and SAF2016-80305-P), Instituto de Salud Carlos III (ISCIII)-Fondo Europeo de Desarrollo Regional (FEDER) a way to build Europe (PI13/01488; PI15/01016, RD12/0042/0024, RD12/0042/0053, CIBER de Enfermedades Cardiovasculares), COST BM1301, ĹOréal-FWIS-Spain and Sociedad Espa ola de Arterioesclerosis (Beca SEA 2016 para investigación básica). AMB was supported by the Ramón y Cajal Program (RYC-2010–06473). RMT was supported through grants from the Canadian Institutes of Health Research and the British Heart Foundation. A part of the study was presented at the 20th Annual Meeting of the European Council for Cardiovascular Research (ECCR), Poiano, Lake Garda, Italy (abstract was published in High Blood Pressure & Cardiovascular Prevention, Volume 23, Issue 4, pp 405–421)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors

  • Galán, María
  • Varona, Saray
  • Orriols, Mar
  • Rodríguez, José Antonio
  • Aguiló, Silvia
  • Dilmé, Jaume
  • Camacho, Mercedes
  • Martínez-González, José
  • Tejedor-Rodríguez, Cristina
Clinical management of abdominal aortic aneurysm (AAA) is currently limited to elective surgical repair because an effective pharmacotherapy is still awaited. Inhibition of histone deacetylase (HDAC) activity could be a promising therapeutic option in cardiovascular diseases. We aimed to characterise HDAC expression in human AAA and to evaluate the therapeutic potential of class I and IIa HDAC inhibitors in the AAA model of angiotensin II (Ang II)-infused apolipoprotein-E-deficient (ApoE(-/-)) mice. Real-time PCR, western blot and immunohistochemistry evidenced an increased expression of HDACs 1, 2 (both class I), 4 and 7 (both class IIa) in abdominal aorta samples from patients undergoing AAA open repair (n=22) compared with those from donors (n=14). Aortic aneurysms from Ang-II-infused ApoE(-/-) mice exhibited a similar HDAC expression profile. In these animals, treatment with a class I HDAC inhibitor (MS-275) or a class IIa inhibitor (MC-1568) improved survival, reduced the incidence and severity of AAA and limited aneurysmal expansion evaluated by Doppler ultrasonography. These beneficial effects were more potent in MC-1568-treated mice. The disorganisation of elastin and collagen fibres and lymphocyte and macrophage infiltration were effectively reduced by both inhibitors. Additionally, HDAC inhibition attenuated the exacerbated expression of pro-inflammatory markers and the increase in metalloproteinase-2 and -9 activity induced by Ang II in this model. Therefore, our data evidence that HDAC expression is deregulated in human AAA and that class-selective HDAC inhibitors limit aneurysm expansion in an AAA mouse model. New-generation HDAC inhibitors represent a promising therapeutic approach to overcome human aneurysm progression., This work was supported by the Spanish Ministerio de Economía y Competitividad (MINECO)-Instituto de Salud Carlos III (ISCIII) [grants PI15/01016 and PI12/01952 to C.R.; SAF2012-40127 to J.M.-G.; SAF2013-46707-R to M.C., RD12/0042/0053 to J.M.-G. and C.R.; RD12/0042/0051 to MC and RD12/0042/0009 to J.A.R.]. The study was co-founded by Fondo Europeo de Desarrollo Regional (FEDER)-The way to build Europe. M.G. was supported by funds provided by ISCIII (Sara Borrell program)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Circulating CCL20 as a New Biomarker of Abdominal Aortic Aneurysm

  • Soto, Begoña|||0000-0002-5965-1292
  • Gallastegi Mozos, Teresa|||0000-0002-6437-6571
  • Rodríguez, C.
  • Martínez-González, José|||0000-0002-3894-7166
  • Escudero, José Román|||0000-0003-3929-6403
  • Vila, L.
  • Camacho, Mercedes|||0000-0001-5970-3294
Autoimmunity appears to play a role in abdominal aortic aneurysm (AAA) pathology. Although the chemokine CCL20 has been involved in autoimmune diseases, its relationship with the pathogenesis of AAA is unclear. We investigated CCL20 expression in AAA and evaluated it as a potential biomarker for AAA. CCL20 was measured in plasma of AAA patients (n = 96), atherosclerotic disease (AD) patients (n = 28) and controls (n = 45). AAA presence was associated with higher plasma levels of CCL20 after adjustments for confounders in the linear regression analysis. Diagnostic performance of plasma CCL20 was assessed by ROC curve analysis, AUC 0.768 (CI:0.678-0.858; p<0.001). Classification and regression tree analysis classified patients into two CCL20 plasma level groups. The high-CCL20 group had a higher number of AAA than the low-CCL20 group (91% vs 54.3%, p< 0.001). mRNA of CCL20 and its receptor CCR6 were higher in AAA (n = 89) than in control aortas (n = 17, p<0.001). A positive correlation was found between both mRNA in controls (R = 0674; p = 0.003), but not in AAA. Immunohistochemistry showed that CCR6 and CCL20 colocalized in the media and endothelial cells. Infiltrating leukocytes immunostained for both proteins but only colocalized in some of them. Our data shows that CCL20 is increased in AAA and circulating CCL20 is a high sensitive biomarker of AAA.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Lysyl oxidase (LOX) limits VSMC proliferation and neointimal thickening through its extracellular enzymatic activity

  • Varona, Saray|||0000-0002-7375-313X
  • Orriols, Mar
  • Galán, María|||0000-0002-4758-8388
  • Guadall, Anna|||0000-0002-7821-8582
  • Cañes Esteve, Laia|||0000-0002-9579-1321
  • Aguiló, Silvia|||0000-0003-0672-8388
  • Sirvent, Marc|||0000-0001-5912-8760
  • Martínez-González, José|||0000-0002-3894-7166
  • Rodríguez, Cristina|||0000-0002-6472-5647
Lysyl oxidase (LOX) plays a critical role in extracellular matrix maturation and limits VSMC proliferation and vascular remodeling. We have investigated whether this anti-proliferative effect relies on the extracellular catalytically active LOX or on its biologically active propeptide (LOX-PP). High expression levels of both LOX and LOX-PP were detected in the vascular wall from transgenic mice over-expressing the full-length human LOX cDNA under the control of SM22α promoter (TgLOX), which targets the transgene to VSMC without affecting the expression of mouse LOX isoenzymes. TgLOX VSMC also secrete high amounts of both mature LOX and LOX-PP. Wild-type (WT) mouse VSMC exposed to VSMC supernatants from transgenic animals showed reduced proliferative rates (low [H]-thymidine uptake and expression of PCNA) than those incubated with conditioned media from WT cells, effect that was abrogated by β-aminopropionitrile (BAPN), an inhibitor of LOX activity. Lentiviral over-expression of LOX, but not LOX-PP, decreased human VSMC proliferation, effect that was also prevented by BAPN. LOX transgenesis neither impacted local nor systemic inflammatory response induced by carotid artery ligation. Interestingly, in this model, BAPN normalized the reduced neointimal thickening observed in TgLOX mice. Therefore, extracellular enzymatically active LOX is required to limit both VSMC proliferation and vascular remodeling.